Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection

AIDS Patient Care and STDs

Volumn 23, Issue 10, 2009, Pages 815-824

  Lai, Shenghan ^a   Bartlett, John ^a   Lai, Hong ^a   Moore, Richard ^a   Cofrancesco, Joseph ^a   Pannu, Harpreet ^a   Tong, Wenjing ^a   Meng, Wei ^a,b   Sun, Hui ^a,c   Fishman, Elliot K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FUDAN UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; COCAINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DRUG EFFECT; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; SEX RATIO;

ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COCAINE-RELATED DISORDERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70350123521     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0048     Document Type: Article

References (23)

1. Eugenin EA, Morgello S, Klotman ME, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: Implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 2008; 172:1100-1111.
2. Stein JH. Cardiovascular risks of antiretroviral therapy. N Engl J Med 2007;356:1773-1775.
3. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-710.
4. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2004.
5. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
6. Jericó C, Knobel H, Calvo N, et al. Subclinical carotid atherosclerosis in HIV-infected patients: Role of combination antiretroviral therapy. Stroke 2006;37:812-817.
7. Sension M, Andrade Neto JL, et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 2009;51:153-162.
8. Currier JS, Kendall MA, Henry WK, et al. Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007;21:1137-1145.
9. D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371: 1417-1426.
10. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008;22:1615-1624.
11. Lai S, Fishman EK, Lai H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis 2008;46:600-610.
12. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-542.
13. Hosmer DW, Lemeshow S. Applied Logisitc Regression, 2nd ed. New York: Wiley, 2000.
14. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
15. Mittlbock M, Schemper M. Explained variation for logistic regression. Stat Med 1996;15:1987-1997.
16. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
17. Burke AP, Kolodgie FD, Farb A, Virmani R. Pathogenesis and significance of calcification in coronary atherosclerosis. In: Virmani R, Narula J, Leon MB, Willerson JT, eds. The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management. Malden, MA: Blackwell, 2007, pp. 77-94.
18. Hausleiter J, Meyer T, Hadamitzky M, Kastrati A, Martinoff S, Schömig A. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol 2006;48:312-318.
19. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerosis lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Circulation 1995;92:1355-1374.
20. Tang W, Detrano RC, Brezden OS, et al. Racial differences in coronary calcium prevalence among high risk adults. Am J Cardiol 1995;75:1088-1091.
21. Detrano R, Wong N, Tang W, et al. Prognostic significance of cardiac cine fluoroscopy for coronary calcific deposits in asymptomatic high risk subjects. J Am Coll Cardiol 1994; 24:354-358.
22. Doherty TM, Tang W, Detrano RC. Racial differences in the significance of coronary calcium in asymptomatic black and white subjects with coronary risk factors. J Am Coll Cardiol 1999;34:787-794.
23. Doherty TM, Detrano RC, Mautner SL, et al. Coronary calcium: The good, the bad, and the uncertain. Am. Heart J 1999; 137:806-814.